New combo therapy targets tough lung cancers

NCT ID NCT07603791

Not yet recruiting Disease control Sponsor: Shanghai Allink Biotherapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called ALK202 combined with other medicines for people with advanced non-small cell lung cancer. The trial will include 252 participants and aims to see if the combinations are safe and can shrink tumors. It is divided into two phases: first to find the right dose, then to check how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALK202 (an investigational drug) combined with osimertinib, ivonescimab, or carboplatin
What this could lead to: If successful, this could point toward new combination treatments for advanced non-small cell lung cancer, especially for patients who have not responded to standard therapies.
What could go wrong: This is an early Phase 2 study with only 252 participants, so results may not apply to all patients. The combinations may cause side effects or fail to shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)

More trials for these conditions

Other studies related to the condition(s) this trial covers.